Back to Search Start Over

Crystal structures of coronaviral main proteases in complex with the non-covalent inhibitor X77.

Authors :
Jiang H
Li W
Zhou X
Zhang J
Li J
Source :
International journal of biological macromolecules [Int J Biol Macromol] 2024 Sep; Vol. 276 (Pt 1), pp. 133706. Date of Electronic Publication: 2024 Jul 07.
Publication Year :
2024

Abstract

Main proteases (M <superscript>pro</superscript> s) are a class of conserved cysteine hydrolases among coronaviruses and play a crucial role in viral replication. Therefore, M <superscript>pro</superscript> s are ideal targets for the development of pan-coronavirus drugs. X77, previously developed against SARS-CoV M <superscript>pro</superscript> , was repurposed as a non-covalent tight binder inhibitor against SARS-CoV-2 M <superscript>pro</superscript> during COVID-19 pandemic. Many novel inhibitors with favorable efficacy have been discovered using X77 as a reference, suggesting that X77 could be a valuable scaffold for drug design. However, the broad-spectrum performance of X77 and underlying mechanism remain less understood. Here, we reported the crystal structures of M <superscript>pro</superscript> s from SARS-CoV-2, SARS-CoV, and MERS-CoV, and several M <superscript>pro</superscript> mutants from SARS-CoV-2 variants bound to X77. A detailed analysis of these structures revealed key structural determinants essential for interaction and elucidated the binding modes of X77 with different coronaviral M <superscript>pro</superscript> s. The potencies of X77 against these investigated M <superscript>pro</superscript> s were further evaluated through molecular dynamic simulation and binding free energy calculation. These data provide molecular insights into broad-spectrum inhibition against coronaviral M <superscript>pro</superscript> s by X77 and the similarities and differences of X77 when bound to various M <superscript>pro</superscript> s, which will promote X77-based design of novel antivirals with broad-spectrum efficacy against different coronaviruses and SARS-CoV-2 variants.<br />Competing Interests: Declaration of competing interest The authors declare that there is no conflicts of interests.<br /> (Copyright © 2024 Elsevier B.V. All rights reserved.)

Details

Language :
English
ISSN :
1879-0003
Volume :
276
Issue :
Pt 1
Database :
MEDLINE
Journal :
International journal of biological macromolecules
Publication Type :
Academic Journal
Accession number :
38981557
Full Text :
https://doi.org/10.1016/j.ijbiomac.2024.133706